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Objective: An association between hypothyroidism (HT) and oral lichen 
planus (OLP) has been reported.  However, the mechanisms that could 
explain this association remain unresolved. This study aimed to evaluate the 
expression of thyroid-stimulating hormone (TSH) and thyroid-stimulating 
hormone receptor (TSHR) in healthy oral mucosa and in OLP lesions of 
individuals with and without HT. Material and methods: 
Immunohistochemical expression of TSH and TSHR was studied in oral 
mucosal biopsies obtained from 14 OLP patients with HT, 14 OLP patients 
without HT and 10 healthy controls without oral mucosal lesions. Gene 
expression of TSHR was investigated by using three different PCR 
techniques in oral mucosal samples from 7 OLP patients with HT, 3 OLP 
patients without HT, 9 healthy controls and in cultured human oral epithelial 
cells. Gene expression of TSH was examined by employing 2 PCR 
techniques in oral mucosal samples from 2 OLP patients with HT, 2 OLP 
patients without HT and 4 healthy controls. Results: TSH and TSHR 
stainings were negative in the studied oral mucosal specimens. Gene 
quantification assays demonstrated negative gene expression of TSH and 
TSHR in clinical and in vitro samples. Conclusions: These results suggest 
that TSH and TSHR may not be commonly involved in the pathogenetic 
mechanism that could explain the association between OLP and 
hypothyroidism.  
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1. Introduction 
Lichen planus is a chronic inflammatory condition that can affect skin and 
mucous membranes including oral mucosa [1].  Oral lichen planus (OLP) 
presents as bilateral reticular, plaque-like, papular, atrophic, erosive or 
bullous lesions that affect predominantly the buccal mucosa, gingiva and 
tongue but can also be seen anywhere on the oral mucosa [2,3]. The disease 
has periodic exacerbation and remission, and only symptomatic treatment 
exists [3].  
 The prevalence of OLP in general population is estimated to be 0.2-
2% [2]. OLP is more common in females and the age of onset is generally 
between 30 and 60 years [4].  Oral lichen planus has around 1 % risk of 
malignant transformation [5].  
The precise etiology of OLP is unknown. The pathogenesis of OLP 
is not completely understood, but both antigen-specific and non-specific 
mechanisms seem to be involved [6,7]. Oral microbiota composition, 
genetic factors, trauma, stress and infections have been suggested as 
predisposing factors for OLP [4,8]. 
Some systemic factors have been associated with OLP. Based on 
systematic reviews and meta-analyses [9 and 10], hepatitis C virus is more 
common in OLP patients in the Middle East (n=583, OR=6.01, 95% CI: 
1.47-24.53), Asia (n=900, OR=6.87, 95% CI: 1.42-33.15), Mediterranean 
countries (n=1615, OR= 6.99, 95% CI: 4.92–9.94) and the USA (n=54, 
OR= 5.09; 95% CI: 1.33–19.41). 
In a recent meta-analysis [11], OLP and thyroid diseases in general 
(n= 1846) showed a significant association (OR=2.1, 95% CI:1.47-3.01), 
and in two of the four studies analyzed (n=675), OLP associated with HT 
(OR=1.83, 95% CI:1.16-2.89). Furthermore, thyroxin medication is more 
common in OLP patients compared to controls [12,13,14]. However, the 
factors that could explain the association between OLP and HT are still 
unclear.   
 Thyroid-stimulating hormone (TSH), also known as thyrotropin, is a 
pituitary hormone that stimulates the thyroid gland to produce thyroxine 
(T4), and triiodothyronine (T3) in response to negative feedback mechanism 
involving free T3 (FT3) and T4 (FT4). T3 is the biologically important 
active hormone that stimulates metabolism [15].  
 Thyroid-stimulating hormone receptor (TSHR) on the thyroid 
follicular cells is a member of the family of G protein-coupled receptors and 
is the primary regulator of thyroid hormone synthesis and secretion [15]. 
The expression of TSHR is not restricted to the thyroid gland.  Active 
TSHR has been detected in a variety of human and animal tissues, including 
osteoblasts, osteoclasts, bone marrow cells, cardiomyocytes, adipocytes, 
fibroblasts and skin keratinocytes. [16,17] 
 There is little information about the expression of thyroid proteins in 
the normal oral mucosa or in OLP lesions. In one study [18] TSHR 
expression was upregulated in OLP lesions in patients receiving thyroxine 
supplement medication compared to healthy oral mucosa of healthy 
controls. However, thyroglobulin (Tg) and thyroid peroxidase (TPO) 
expression were not detected in any of the studied samples [18].  
 In the present study we aimed to investigate the protein and gene 
expression of TSH and TSHR in normal oral mucosa of healthy subjects and 
in OLP lesions of patients with and without HT.  
 
2. Materials and methods 
Patients and samples 
The tissue samples for immunohistochemical study comprised of oral 
mucosal diagnostic biopsies from 14 OLP patients with HT (mean age 59.1 
years, range 37–72) and 14 age- (+/- 1 year) and sex-matched OLP patients 
without HT (mean age 58.9 years, range 37–72) collected from the archives 
of Kuopio University Hospital, Department of Clinical Pathology. The 
diagnosis of HT was confirmed from medical records. 13 of the patients had 
HT due to Hashimoto´s thyroiditis and one patient had partial 
thyroidectomy due to goiter and subsequent hypothyroidism. In the OLP 
with HT group, 11 samples were from the buccal mucosa, 2 from the tongue 
and 1 from the gingiva. In the OLP without HT group, 11 samples were 
from the buccal mucosa and 3 from the tongue. Further clinical and 
demographic characteristics of the patients are listed in Table I.  The 
diagnosis of OLP in the study was made combining the clinical and 
histopathological features according to the criteria presented in a AAOMP 
position paper [19]. The control samples consisted of 10 oral mucosal 
biopsies taken from systemically healthy control donors (mean age 26 years, 
range 12-51). Four of the control specimens were from healthy buccal 
mucosa and 6 were taken during surgical removal of third molars from the 
mucosa next to the teeth. Seven healthy thyroid gland tissue samples from 
the pathology archives of Oulu University hospital were used as positive 
controls. All samples were fixed in 10% neutral buffered formalin and 
embedded in paraffin. 
 In addition, fresh frozen tissue samples from OLP lesions of patients 
with Hashimoto´s thyroiditis (n=7, mean age 68, range 60-78) and without 
HT (n=3, mean age 57, range 48-70) as well as control samples consisting 
of healthy buccal mucosa from systemically healthy donors (n=9, mean age 
26, range 23-34) were collected and preserved in RNAlater (Thermo Fisher 
Scientific, Carlsbad, CA, USA) for later PCR based analyses. In the OLP 
with HT group, 5 samples were from the buccal mucosa, 1 was from the 
tongue and 1 from the gingiva. In the OLP without HT group, 2 samples 
were from the buccal mucosa and 1 from the gingiva. Further clinical and 
demographic characteristics of the study patients are listed in Table II.  
 This study was approved by the ethics committees of the Northern 
Ostrobothnian Hospital District (46/2013) and the Helsinki University 
Hospital. The Research Ethics Committee of the Northern Savo Hospital 
District in Kuopio received information of the approval. The approval for 
use of archival tissue material was granted by the National Supervisory 
Authority for Welfare and Health (VALVIRA). 
 
Immunohistochemical staining 
Tissue sections were deparaffinized in xylene and rehydrated in ethanol 
multi-concentration series. The retrieval of the antigens was performed as 
follows: the slides were placed in 700 ml of 10 mM citrate buffer, pH 6.0, 
and microwaved in a microwave processing labstation for Histology 
(HACKER Instruments & Industries Inc., Winnsboro, SC, USA) according 
to the manufacturer’s instructions. For blocking the nonspecific background, 
sections were incubated in 1% H2O2 for 10 min and washed in 10 mM 
phosphate buffered 140 nM saline, pH 7.4 (PBS) and then incubated in 10% 
normal horse serum (Vector Laboratories, Burlingame, CA, USA) at RT for 
1 hour.  
Sections were then incubated overnight in 1 µg/ml mouse anti-
human monoclonal thyroid stimulating hormone receptor antibody (TSHR; 
clone 4 C1; Bio-Rad Corp., Hercules, CA, US); 2) 10 µg/ml mouse anti-
human monoclonal thyroid stimulating hormone antibody (TSH; clone 
0042; DAKO, Glostrup, Denmark), at +4ºC and washed in PBS. Biotin-
conjugated secondary anti-mouse antibodies (Vector Laboratories; 1:200) 
were applied for 1 hour at RT and washed in PBS. Later, avidin–biotin–
peroxidase complex (ABC, Vector Laboratories; 1:200) were then applied 
for 1 hour at RT and washed in PBS. For colour development, 
diaminobenzidine tetrahydrochloride was applied for 10 min at RT and 
washed in dH2O. Counterstaining of the slides was performed using 
hematoxylin and the slides were mounted in Mountex (HistoLab, 
Gothenburg, Sweden). The optimal working concentration for each antibody 
was confirmed in pilot experiments using a series of dilutions. The 
specificity of each antibody was confirmed with positive control samples 
(thyroid tissues). Negative control sections were incubated without the 
primary antibody. 
 
Cell culture and maintenance 
Human oral keratinocytes HOKs isolated from normal oral mucosa 
(ScienCell, Uppsala, Sweden) were cultured in 75 cm2 flask containing oral 
keratinocyte medium OKM (ScienCell, Uppsala, Sweden) enriched with 
growth factors and antibiotics. Confluent cells were detached using 
trypsin/EDTA solution (ScienCell, Uppsala, Sweden) and plated in 6-
multiwell cell culture plates (BD Falcon, Lawrence, KS, USA). Once the 
wells were approximately 90% confluent, cells were lysed using RLT buffer 
(Qiagen, Düsseldorf, Germany) and stored at -80ºC for further use. The 
normal human thyroid follicular cells (N-Thyr-ori 3-1) were purchased from 
Health Protection Agency Culture Collection (Salisbury, UK). The cells 
were cultured in RPMI1640 supplemented with 10% FBS, 1% penicillin-
streptomycin and 1% L-glutamine. The human thyroid follicular cancer 
cells (ML-1) were generously provided by Dr. Johann Schönberger 
(University of Regensburg, Germany). The cells were grown in DMEM 
supplemented with 10% FBS, 1% L-glutamine and 1% penicillin-
streptomycin. The cell cultures were maintained in the incubators with a 
water-saturated atmosphere of 5% CO2 at 37°C. 
 
Isolation of Total RNA 
Total RNA was isolated from HOKs using the RNeasy Mini Kit (Qiagen, 
Düsseldorf, Germany), while RNA from clinical samples were isolated 
using miRNeasy Mini Kit and QIAcube workstation (Qiagen, Düsseldorf, 
Germany), where QIAzol Lysis Reagent was added and then samples were 
homogenized with Tissuelyser 3x2 min, 50 Hz. The assay was performed 
according to the manufacturer’s instructions. Total RNA from N-thyr Ori 3-
1 and ML-1 cells was extracted with AurumTM Total RNA Mini Kit (Bio-
Rad; CA, USA) according to the manufacturer’s instructions. RNA integrity 
was checked by gel electrophoresis and RNA concentration and purity was 
determined with NanoVue Plus (Healthcare Bio-Sciences AB; Uppsala, 
SE). 
 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Complementary DNA strands were synthesized using iScript cDNA 
synthesis kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). Quantitative 
RT-PCR was run using 2 µl cDNA and 250 nM primers in iQ SYBR Green 
supermix in iQTM5 Multicolour RT-PCR Detection System (Bio-Rad 
Laboratories Inc.). GAPDH and RPLP0 were used as the housekeeping 
reference genes. Primer sequences are listed in Table III. 
 
Droplet Digital Polymerase Chain Reaction (ddPCR) 
The ddPCR is a highly-sensitive new technology that is able to perform an 
absolute nucleic acid quantification without establishment of a standard 
curve [20]. The ddPCR is proven to have a low detection limit and to be 
sensitive enough to detect only few positive molecules. The utilized final 
volume of 20 μl reaction mix contained 10 μl of QX200™ EvaGreen® 
ddPCR™ Supermix (Bio-Rad Laboratories), 2 μl of cDNA, 1 μl primers. 
The annealing temperature was set to 60°C. The assay was performed using 
QX200™ Droplet-Generator and QX200™ Droplet Digital™ PCR Systems 
(Bio-Rad Laboratories) according to the manufacturer’s instructions. 
 
Qualitative end point PCR 
Complementary DNA was synthesized with SuperScript IV VILO kit 
(Invitrogen by Thermo Fisher Scientific, Carlsbad, CA, USA) from equal 
amounts of RNA (1µg). Reaction mixtures without reverse transcriptase 
(RNA control) or RNA (No template control-NTC) were employed as 
negative controls to maintain a check that the sample RNA preparations and 
PCR mixtures were not contaminated with any genomic DNA. The 
information about primer sequences and the PCR cycling settings are 
mentioned in Table III. 
 
Microscopic imaging 
The immunostained sections were evaluated by one of the authors (AS). 
Fully-automated Leica DM6000 microscope with Leica DFC365-FX 
camera (Leica Microsystems, Wetzlar, Germany) was used for imaging of 




The positive control tissue showed strong immunoexpression of TSH and 
TSHR. The healthy oral mucosal tissue and OLP lesional tissue from 
patients with and without HT did not show immunoreactivity for TSH and 
TSHR (Figure 1).  
 
PCR-based analyses 
qRT-PCR and ddPCR for TSH from OLP lesions from patients with HT 
(n=2) and without HT (n=2) as well as healthy oral mucosa from controls 
(n=4) indicated negative expression (data not shown). qRT-PCR, ddPCR 
and qualitative end point PCR for TSHR from OLP clinical samples (OLP-
HT n=7, OLP-nonHT n=3), healthy control samples (n=9) were also 
negative, while thyroid cells (ML-1, N-Thyr-ori) indicated strong positive 
expression (Figures 2 and 3).  Furthermore, we were not able to detect TSH 
nor TSHR genes in mRNA from cultured normal HOKs (data not shown).  
 
4. Discussion 
A positive and statistically significant correlation between OLP and thyroid 
disease and between OLP and HT was reported in a meta-analysis [11]. The 
authors suggest that thyroid disease might be involved in the pathogenesis 
of OLP, or that OLP is a clinical manifestation of thyroid disease [11]. 
However, the mechanism behind the association of OLP and thyroid disease 
is still unknown. 
 Thyroid medication as a cause of OLP and oral lichenoid lesions 
(OLL) has been suspected. In a study [21] where an association between 
hypothyroidism and OLP was found, a subanalysis involving only patients 
with a history of thyroid disease (most of them had HT) provided no 
evidence for thyroxin medication per se of having effect on OLL/OLP. 
Contrary to this, a study [13] where the medication profile of patients with 
OLP (n=956) was compared with dental patients with no oral mucosal 
lesions found that levothyroxine sodium medication was associated with 
OLP (multivariate OR 3.39, 95% CI: 2.09–5.46, P < 0.0001). The same 
authors later interpreted, based on the scarcity of reports of lichenoid 
reactions caused by levothyroxine and on the short half-life of the drug, that 
their findings are indicative of association of HT and OLP, rather than 
thyroxin medication and OLP [22].  
A molecular mimicry hypothesis for both HT and lichen planus has 
been proposed. This hypothesis suggests that structural similarity between 
microbial antigens and human autoantigens can turn a defensive immune 
reaction into an autoimmune reaction in genetically predisposed subjects. 
[23] 
 The association between OLP and HT could also be explained by a 
common autoimmune process. OLP is considered to be a T-cell-mediated 
autoimmune disease which is characterized by auto-cytotoxic CD8 + T cells 
triggering apoptosis of the basal cells of the oral epithelium [24]. 
Hashimoto´s thyroiditis is the most common cause of HT. It is an organ 
specific autoimmune disease in which lymphocytic infiltration of the 
thyroid parenchyma is seen. [25] The pathogenesis of the disease involves 
the formation of anti-thyroid antibodies that attack thyroid stroma causing 
progressive fibrosis. The most common laboratory findings in Hashimoto’s 
thyroiditis include an elevated TSH level and normal to low FT4. [26] 
Ninety per cent of patients with this disease have elevated levels of 
circulating anti-TPO antibodies, and high serum Tg antibody concentrations 
are present in 20 to 50 percent of these patients [27]. In Hashimoto´s 
thyroiditis only 6% of patients are seropositive for anti-TSHR [28].  
 Indeed, it has been suggested that circulating anti-thyroid antibodies 
could contribute to trigger an autoimmune response in the oral mucosa, also 
in patients with asymptomatic chronic autoimmune thyroiditis [29].  Two 
studies [30,31] found significantly higher titers of anti-TPO and anti-Tg in a 
group of patients with OLP who did not have any other autoimmune 
diseases. However, in another study [18] no association was found between 
elevated serum anti-Tg, anti-TPO or anti-TSHR antibodies and OLP; the 
authors found altered levels of TSH and FT4 more often in OLP patients 
without previously diagnosed thyroid disease than in the general population. 
In addition, the same study [18] reported positive TSHR immunostaining in 
the basal epithelial layer in OLP lesions in patients with levothyroxine 
medication but not in controls and significantly higher expression of TSHR 
by qPCR analysis in OLP lesions compared to controls. It was therefore 
suggested that TSHR might be associated with OLP pathogenesis [18]. In 
contrast with this, the monoclonal antibodies applied in our study, showed a 
negative expression of both TSH and TSHR in healthy oral mucosa and 
OLP lesions compared with the strongly-stained thyroid tissue controls. 
Additionally, these findings were also in line with the gene quantification 
data, which indicated negative TSH and TSHR gene levels in clinical as well 
as in vitro cell culture samples. Such variation in results in our or in the 
reported cases could be attributed to many factors including e.g. the 
clonality of the antibodies, alterations in blocking, or optimization of the 
other methods [32].  
Although our current results imply that TSH and TSHR, at both 
protein and gene level, are not at least commonly expressed in OLP lesions, 
it is possible that there is a subgroup of OLP patients with thyroid disease 
where these markers are expressed and could therefore explain, at least in 
part, the association between OLP and autoimmune thyroid disease. Among 
the limitations of the present study are a very limited number of studied 
samples and lack of functional assays. Therefore, based on our results, any 
solid conclusions cannot be made about the role of TSH and TSHR in OLP. 
Further investigations are needed to determine the pathogenetic basis 
between autoimmune thyroid disease and OLP. 
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Table I.  
Clinical and demographic characteristics of the OLP patients (immunohistochemical study) 
Characteristic Age/Sex Diagnosis of thyroid disease Other comorbidities Medications Allergies 
OLP patients with HT 
1 58/F Hashimoto´s thyroiditis (HT) Arterial hypertension Candesartan, levothyroxine - 
2 61/F HT Sensory neural hearing loss, nasal 
polyposis  
Mometasone furoate, levothyroxine - 
3 53/F HT Osteoporosis, allergic asthma, chronic 
brochitis, bile acid diarrhea, depression, 
migraine, cutaneous LP 
Alendronate, escitalopram, sodium valproate, cetirizine, 
quetiapine, esomeprazole, montelukast, levothyroxine, 
fluticasone propionate/salmenterol, tiotropium, 
beclometasone dipropionate, buprenorphine, vaginal 
estrogen 
Pollen, cat, dust mite, 
cephalosporin, penicillin 
4 37/F HT Migraine Levothyroxine Pollen 
5 59/F HT Arterial hypertension, leg and back pain, 
cutaneous LP 
Enalapril maleate, levothyroxine, paracetamol - 
6 68/F HT Arterial hypertension, asthma, arthrosis, 
celiac disease 
Estradiol, levothyroxine, bisoprolol, nifedipine  - 
7 65/F HT Cutaneous LP Levothyroxine - 
8 53/F HT Arterial hypertension, arthrosis, 
hypercholesterolemia 
Esomeprazole, valsartan, levothyroxine - 
9 53/F HT - Levothyroxine - 
10 52/F Hypothyroidism due to goiter and 
partial removal of thyroid gland 
DM1, arterial hypertension, 
hypercholesterolemia 
Levothyroxine, simvastatin, insulin glargine, 
acetylsalicylic acid, insulin aspart 
Doxycycline 
11 68/F HT Heart failure, arterial hypertension, 
arrhythmia, periodical asthma, heartburn 
Levothyroxine, ramipril, simvastatin, acetylsalicylic acid, 
amlodipine, metoprolol 
Sulfonamide 
12 72/F HT Paget´s disease Levothyroxine, zoledronic acid Penicillin 
13 60/F HT Asthma, heart failure - - 
14 68/M HT Arterial hypertension Levothyroxine, amlodipine, bisoprolol - 
 
OLP patients without HT 
1 57/F - Arthrosis, arterial hypertension Losartan, meloxicam, paracetamol, zolpidem Penicillin 
2 60/F - Cutaneous dermografism - Birch, nuts, celery, paprika 
3 54/F - Arterial hypertension, osteoporosis, 
chronic cold, chronic back pain, 
cutaneous lichen 
Bisoprolol, losartan, ebastine, lansoprazole, tramadol, 
gabapentin, venlafaxine, alendronate, paracetamol, 
temazepam 
Birch 
4 37/F - Vitamin B12 deficiency Hydroxocobalamin - 
5 60/F - Lymphocytic colitis, 
hypercholesterolemia 
Mesalazine, loperamide, acetylsalicylic acid, simvastatin  Sulfonamide 
6 67/F - Carcinoma in corpus area, fibromyalgia Amitriptyline - 
7 66/F - Arterial hypertension, DM2, 
bronchiectasis 
Bisoprolol+hydrochlorothiazide,metformin hydrochloride, 
acetylsalicylic acid, glimepiride, simvastatin 
- 
8 53/F - Rheumatoid arthritis, Sjögren syndrome, 
psoriasis 
Sulfasalazine, hydroxychloroquine Sodium aurothiomalate, 
etanercept 
9 52/F - Asthma - Hydrocortisone, nickel, 
tixocortol pivalate, mercury 
10 51/F - Arterial hypertension Medication for hypertension - 
11 68/F - Arthrosis Glucosamine, estradiol - 
12 72/F - Arterial hypertension, restless legs 
syndrome 
Amiloride hydrochloride dihydrate, pramipexole, 
tafluprost 
pollen 
13 60/F - Otitis media serosa, 
hypercholesterolemia 
Simvastatin - 
14 67/M - Coronary artery disease Nitroglycerin, metoprolol - 
 
 
Table II.  
















Levothyroxine, ramipril, simvastatin, 
acetylsalicylic acid, amlodipine, 
metoprolol 
Sulfonamide 
P2 76/F HT Essential 
thrombocythemia 
Levothyroxine, acetylsalicylic acid, 




P3 48/M - Cerebral infarction, 
sleep apnea 
Dipyridamole + acetylsalicylic acid, 
simvastatin 
- 
P4 70/M - Arterial hypertension Bisoprolol, felodipine, losartan, 
cetirizine 
- 










syndrome, leaky heart 
valve, pulmonal 
hypertension, 




salbutamol, fluticasone propionate  
Pollen, odors 
P7 60/F HT Arterial hypertension Levothyroxine, candesartan - 












attack, celiac disease, 
mental issues 
Levothyroxine, alendronic acid, 
losartan, escitalopram, acetylsalicylic 
acid, rosuvastatin 
- 
P10 53/M - Arthrosis - - 
 
Table III. 
A. Sequences of the used human primer sequences. 
Gene                  Forward                      Reverse 
TSH 5′-ATGGATTACTACAGAAAATATGC-3′ 5′-AGATTTTGTATAATAACAAGTACT-3′ 
TSHR 5′-GCTTTTCAGGGACTATGCAATGAA-3′ 3′-AGAGTTTGGTCACAGTGACGGGAA-5′ 
GAPDH 5′-AAGGTCATCCCTGAGCTG-3′ 5′-TGCTGTAGCCAAATTCGTTG-3′ 
RPLP0 5′-GGCGACCTGGAAGTCCAACT-3′ 5′-CCATCAGCACCACAGCCTTC-3′ 
TSH: Thyroid stimulating hormone; TSHR: Thyroid stimulating hormone receptor; GAPDH: 
Glyceraldehyde 3-phosphate dehydrogenase; RPLP0: Ribosomal protein, large, P0. 
 
 






















Figure 1.  TSH and TSHR are expressed in healthy thyroid tissue.  The 
healthy oral mucosal tissue and OLP lesional tissue from patients without 
HT and with HT do not show immunoreactivity for TSH and TSHR.  
Figure 2. Transcriptional levels of TSHR in healthy samples and OLP 
lesions. The absolute quantification by ddPCR technology revealed a 
negative expression of TSHR in oral mucosal biopsies obtained from 
healthy individuals (H1-H9) and from OLP patients (P1-P10). Human 
thyroid cell lines (ML-1 and N-Thyr-Ori) were used as positive controls and 
they revealed substantial levels of TSHR copies. 
Figure 3. End point qualitative PCR of TSHR on healthy (H1-H9) and 
OLP (P1-10) oral mucosal samples. Normal thyroid cell line (N-Thyr-Ori 
3-1) and follicular thyroid cancer ML-1 are used as positive controls. RNA 
C denotes negative control (without reverse transcriptase) whereas NTC 
denotes no template negative control (without RNA) samples. The TSHR 
product size is 271 bp. 
 
 



